Skip to main content

Table 3 Treatment status

From: Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

Treatment status Use following csDMARD-IR (first-line biologic agent) Use following first bDMARD-IR (second-line biologic agent)
Abatacept TNFi p value Abatacept TNFi p value
n 92 613 105 212
Stopped treatment, n (%) 47 (51.1) 365 (59.5) 0.1404 60 (57.1) 157 (74.1) 0.0031
 Treatment duration, years, mean (SD) 1.57 (1.68) 2.01 (2.23) 0.1068 1.76 (1.78) 1.33 (1.70) 0.1045
 Reasons for stopping, n (%)    0.1351    0.4409
  Inefficacy 28 (59.6) 171 (46.8)   38 (63.3) 86 (54.8)  
  Adverse event 8 (17.0) 76 (20.8)   12 (20.0) 27 (17.2)  
  Lost to follow-up 2 (4.3) 21 (5.8)   0 6 (3.8)  
  Treatment stopped by the patient 3 (6.4) 14 (3.8)   0 4 (2.5)  
  Infections 3 (6.4) 22 (6.0)   2 (3.3) 9 (5.7)  
  Death 0 7 (1.9)   3 (5.0) 4 (2.5)  
Ongoing treatment 45 (48.9) 248 (40.5) 0.1404 45 (42.9) 55 (25.9) 0.0031
 Treatment duration, years, mean (SD) 4.46 (2.99) 6.25 (3.25) 0.0007 4.57 (2.69) 4.15 (2.68) 0.4364
  1. bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR inadequate response, TNFi tumor necrosis factor inhibitor